Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 220 matching drugs for YES1 — including drugs targeting any of its 27 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib YES1 Direct 2
afatinib, dasatinib, palbociclib, everolimus, olaparib YES1 Direct 1
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment YES1 Direct 1
bevacizumab, dasatinib, placebo YES1 Direct 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride YES1 Direct 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method YES1 Direct 1
dasatinib, laboratory biomarker analysis, physiologic testing YES1 Direct 1
dasatinib, mfolfox6 YES1 Direct 1
dasatinib, pharmacological study YES1 Direct 1
dasatinib, temozolomide, placebo, radiation therapy YES1 Direct 1
dasatinib YES1 Direct yes 0
vandetanib YES1 Direct yes 0
adagrasib KRAS SSL via KRAS yes 2
sotorasib KRAS SSL via KRAS yes 2
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab ABL1 SSL via ABL1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab FGFR1 SSL via FGFR1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) ABL1 SSL via ABL1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) FGFR1 SSL via FGFR1 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ABL1 SSL via ABL1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib AKT1 SSL via AKT1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FGFR1 SSL via FGFR1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FGR SSL via FGR 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FYN SSL via FYN 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib LCK SSL via LCK 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MAPK3 SSL via MAPK3 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SRC SSL via SRC 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan FGFR1 SSL via FGFR1 3
pembrolizumab, belzutifan, lenvatinib FGFR1 SSL via FGFR1 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ABL1 SSL via ABL1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel FGFR1 SSL via FGFR1 2
bbi-355, erlotinib, futibatinib FGFR1 SSL via FGFR1 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment ABL1 SSL via ABL1 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment FGR SSL via FGR 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment FYN SSL via FYN 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment LCK SSL via LCK 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment SRC SSL via SRC 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib FGFR1 SSL via FGFR1 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib JAK2 SSL via JAK2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib TNK2 SSL via TNK2 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a FGFR1 SSL via FGFR1 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib JAK2 SSL via JAK2 2
lenvatinib, pembrolizumab FGFR1 SSL via FGFR1 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate FGFR1 SSL via FGFR1 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a FGFR1 SSL via FGFR1 2
nintedanib FGFR1 SSL via FGFR1 yes 2
nintedanib LCK SSL via LCK 2
nintedanib SRC SSL via SRC 2
nintedanib, pembrolizumab FGFR1 SSL via FGFR1 2
nintedanib, pembrolizumab LCK SSL via LCK 2
nintedanib, pembrolizumab SRC SSL via SRC 2
pembrolizumab, lenvatinib FGFR1 SSL via FGFR1 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu FGFR1 SSL via FGFR1 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin FGFR1 SSL via FGFR1 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery FGFR1 SSL via FGFR1 2
regorafenib ABL1 SSL via ABL1 yes 2
regorafenib FGFR1 SSL via FGFR1 2
regorafenib, laboratory biomarker analysis ABL1 SSL via ABL1 2
regorafenib, laboratory biomarker analysis FGFR1 SSL via FGFR1 2
sorafenib, administered orally, ct/mri FGFR1 SSL via FGFR1 2
afatinib, dasatinib, palbociclib, everolimus, olaparib ABL1 SSL via ABL1 1
afatinib, dasatinib, palbociclib, everolimus, olaparib FGR SSL via FGR 1
afatinib, dasatinib, palbociclib, everolimus, olaparib FYN SSL via FYN 1
afatinib, dasatinib, palbociclib, everolimus, olaparib LCK SSL via LCK 1
afatinib, dasatinib, palbociclib, everolimus, olaparib SRC SSL via SRC 1
arsenic trioxide AKT1 SSL via AKT1 1
arsenic trioxide MAPK3 SSL via MAPK3 1
arsenic trioxide, radiation therapy AKT1 SSL via AKT1 1
arsenic trioxide, radiation therapy MAPK3 SSL via MAPK3 1
arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy AKT1 SSL via AKT1 1
arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy MAPK3 SSL via MAPK3 1
atezolizumab, tivozanib FGFR1 SSL via FGFR1 1
bevacizumab, dasatinib, placebo ABL1 SSL via ABL1 1
bevacizumab, dasatinib, placebo FGR SSL via FGR 1
bevacizumab, dasatinib, placebo FYN SSL via FYN 1
bevacizumab, dasatinib, placebo LCK SSL via LCK 1
bevacizumab, dasatinib, placebo SRC SSL via SRC 1
biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, ulixertinib MAPK3 SSL via MAPK3 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging FGFR1 SSL via FGFR1 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography FGFR1 SSL via FGFR1 1
bosutinib ABL1 SSL via ABL1 yes 1
bosutinib FGR SSL via FGR 1
bosutinib SRC SSL via SRC yes 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab FGFR1 SSL via FGFR1 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab LCK SSL via LCK 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab SRC SSL via SRC 1
capivasertib AKT1 SSL via AKT1 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin HSPA5 SSL via HSPA5 1
cisplatin, pemetrexed disodium, sorafenib FGFR1 SSL via FGFR1 1
cytoreductive surgery, perifosine, temsirolimus AKT1 SSL via AKT1 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride ABL1 SSL via ABL1 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride FGR SSL via FGR 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride FYN SSL via FYN 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride LCK SSL via LCK 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride SRC SSL via SRC 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method ABL1 SSL via ABL1 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method FGR SSL via FGR 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method FYN SSL via FYN 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method LCK SSL via LCK 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method SRC SSL via SRC 1
dasatinib, laboratory biomarker analysis, physiologic testing ABL1 SSL via ABL1 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.